150.00 rub.
Buy article

Doxorubicin-induced congestive heart failure and its cell therapy in the experiment

Krуventsov A. V., Khubulava G. G., Alexandrov V. N., Kaluzhnaya L. I.
Federal State Budgetary Military Educational Institution of Higher Education, "S. M. Kirov Military Medical Academy" of the Ministry of defence of the Russian Federation, Akademika Lebedeva 6, St.-Petersburg 194044

Keywords: doxorubicin, congestive heart failure of non-ischemic genesis, ejection fraction, cell therapy, bone marrow mononuclear fraction, ways of cell delivery, cell concentration in cell product

DOI: 10.18087/rhfj.2017.2.2309

Background. Cellular cardioplasty may become a promising method for treatment of heart failure, however, clinical use of this method requires solving several issues. Aim. Searching for an optimally safe and efficient type of the cellular therapy for congestive heart failure (CHF) of non-ischemic origin. Materials and methods. The study was performed on an experimental model of doxorubicin-induced heart failure. Efficacy of the cellular therapy with a bone marrow mononuclear fraction was comparatively analyzed in rats by two parameters – methods of cell product delivery and concentration of cells therein. Results. It was found that first, according to EF and data of myocardial morphology, the combined, intramyocardial and intracoronary method was more effective (at the same concentration of cells in transplant) than its components, i.e., intracoronary and intramyocardial delivery. Second, the efficacy of the combined delivery, as the optimal one, depends on the cell concentration in the cell product – 10 million cells are more effective than 2 million cells. The combined delivery of 10 million cells accepted as the optimal one proved safe and effective in the experimental therapy for doxorubicin-induced CHF in rabbits.
  1. Владимирская Е. Б., Майорова О. А., Румянцев С. А., Румянцев А. Г. Биологические основы и перспективы терапии стволовыми клетками. –М.: Медпрактика-М; 2005. 392 с [Vladimirskaya E. B., Majorova O. A., Rumyanczev S. A., Rumyanczev A. G. Biologicheskie osnovy` i perspektivy` terapii stvolovy`mi kletkami. –M.: Medpraktika-M; 2005. 392 s].
  2. Белоусов Ю. Б., Моисеев В. С., Лепахин В. К. Клиническая фармакология и фармакотерапия. –М.: Универсум паблишинг; 1997. 531 с [Belousov Yu. B., Moiseev V. S., Lepaxin V. K. Klinicheskaya farmakologiya i farmakoterapiya. –M.: Universum pablishing; 1997. 531 s].
  3. Balsam LB, Wagers AJ, Christensen JL, Kofidis T, Weissman IL, Robbins RC. Haematopoietic stem cells adopt mature haematopoietic fates in ischaemic myocardium. Nature. 2004;428(6983):668–73. DOI:10.1038/nature02460.
  4. Nygren JM, Jovinge S, Breitbach M, Säwén P, Röll W, Hescheler J at al. Bone marrow-derived hematopoietic cells generate cardiomyocytes at a low frequency through cell fusion, but not transdifferentiation. Nat Med. 2004;10(5):494–501. DOI:10.1038/nm1040.
  5. Reinecke H, Minami E, Poppa V, Murry CE. Evidence for fusion between cardiac and skeletal muscle cells. Circ Res. 2004;94(6):e56-60. DOI:10.1161/01.RES.0000125294.04612.81.
Krуventsov A. V., Khubulava G. G., Alexandrov V. N., Kaluzhnaya L. I. Doxorubicin-induced congestive heart failure and its cell therapy in the experiment. Russian Heart Failure Journal. 2017;18 (2):152–160

To access this material please log in or register

Register Authorize
Ru En